Definitive Contract 75N93023C00052

This federal contract award, with an ID of 75N91019D00024|75N91020F00014, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports NIAID's goal to better understand the coronavirus, with an initial focus on the ACTIV3 clinical trial. The task order will initiate the management, oversight, and conduct of the NIAID DCR...

This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), awarded Leidos Biomedical Research, Inc. a $62.1 million cost-plus-fixed-fee delivery order contract to initiate management, oversight, and conduct of NIAID's DMID Clinical Trial titled "A Multicenter Platform Evaluating Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults" (short title). Under this contract,...

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to facilitate the conduct of an observational study to characterize patients with COVID-19 infection (10,000 subjects). The contract has a ceiling value of $18,109,529.00 with a period of performance through January 31, 2027. It is a cost-plus-fixed-fee delivery order contract with no set-aside...

This is a Cost Plus Fixed Fee Delivery Order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract has a ceiling value of $11,959,649.00 and is for the NIAID-DMID-ANTIVIRAL PROGRAM FOR PANDEMICS EARLY PHASE CLINICAL TRIAL(S). Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor...

This is a $234,668,497.00 cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports the National Institute of Allergy and Infectious Diseases (NIAID) COVID-19 ACTIV3 program, which aims to develop and implement joint research protocols for studying children with infectious, immunologic, and allergic diseases. The contract has an ultimate completion date of September...

This is a $162,950,791.20 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Leidos, Inc. Research And Development Division. The contract is for biomedical (basic) research and development services, and does not have a set-aside designation. The contract is associated with larger contract vehicles, including the One Acquisition Solution for Integrated Services (OASIS) and Alliant II Governmentwide...

<p>This is a $205,003,103.62 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Modex Therapeutics, Inc. to advance the development of potent, cross-reactive multispecific antibodies for the preparedness countermeasure of COVID-19 and seasonal and highly pathogenic avian influenza. The contract has an ultimate completion date of January 18, 2030. This award is not a set-aside contract.</p>

This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the &quot;DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES&quot;, which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...

This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines &amp; Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...